Evidence map›Paper›PMID 30662943›Full record

Trial reportScience advances2019

Cofilin hyperactivation in HIV infection and targeting the cofilin pathway using an anti-α

Sijia He, Yajing Fu, Jia Guo, Mark Spear, Jiuling Yang, Benjamin Trinité, Chaolong Qin, Shuai Fu, Yongjun Jiang, Zining Zhang and 8 more

Open access · goldAbstract readClinical Trial
In one paragraph

Trial report in Science advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Estradiol inhibits HIV-1Scientific reports · 2022
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Proteomics for cancer drug design.Expert review of proteomics · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 2 countries.

Sijia HeKey Laboratory of AIDS Immunology of National Health Commission, Department of Laboratory Medicine, The First Affiliated Hospital, China Medical University, Shenyang, Liaoning 110001, P. R. China.ORCID 0000-0002-1932-1141
Yajing FuKey Laboratory of AIDS Immunology of National Health Commission, Department of Laboratory Medicine, The First Affiliated Hospital, China Medical University, Shenyang, Liaoning 110001, P. R. China.ORCID 0000-0002-4343-2220
Jia GuoNational Center for Biodefense and Infectious Diseases, School of Systems Biology, George Mason University, Manassas, VA 20110, USA.
Mark SpearNational Center for Biodefense and Infectious Diseases, School of Systems Biology, George Mason University, Manassas, VA 20110, USA.
Jiuling YangNational Center for Biodefense and Infectious Diseases, School of Systems Biology, George Mason University, Manassas, VA 20110, USA.
Benjamin TrinitéDepartment of Basic Science, New York University College of Dentistry, New York, NY 10010, USA.ORCID 0000-0003-3809-042X
Chaolong QinKey Laboratory of AIDS Immunology of National Health Commission, Department of Laboratory Medicine, The First Affiliated Hospital, China Medical University, Shenyang, Liaoning 110001, P. R. China.
Shuai FuKey Laboratory of AIDS Immunology of National Health Commission, Department of Laboratory Medicine, The First Affiliated Hospital, China Medical University, Shenyang, Liaoning 110001, P. R. China.
Yongjun JiangKey Laboratory of AIDS Immunology of National Health Commission, Department of Laboratory Medicine, The First Affiliated Hospital, China Medical University, Shenyang, Liaoning 110001, P. R. China.
Zining ZhangKey Laboratory of AIDS Immunology of National Health Commission, Department of Laboratory Medicine, The First Affiliated Hospital, China Medical University, Shenyang, Liaoning 110001, P. R. China.
Junjie XuKey Laboratory of AIDS Immunology of National Health Commission, Department of Laboratory Medicine, The First Affiliated Hospital, China Medical University, Shenyang, Liaoning 110001, P. R. China.
Haibo DingKey Laboratory of AIDS Immunology of National Health Commission, Department of Laboratory Medicine, The First Affiliated Hospital, China Medical University, Shenyang, Liaoning 110001, P. R. China.
David N LevyDepartment of Basic Science, New York University College of Dentistry, New York, NY 10010, USA.ORCID 0000-0001-9389-5509
Wanjun ChenMucosal Immunology Section, NIDCR, NIH, Bethesda, MD 20892, USA.
Emanuel PetricoinCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA 20110, USA.
Lance A LiottaCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA 20110, USA.
Hong ShangKey Laboratory of AIDS Immunology of National Health Commission, Department of Laboratory Medicine, The First Affiliated Hospital, China Medical University, Shenyang, Liaoning 110001, P. R. China.
Yuntao WuNational Center for Biodefense and Infectious Diseases, School of Systems Biology, George Mason University, Manassas, VA 20110, USA.ORCID 0000-0002-9547-3278
George Mason University · USChinese Academy of Medical Sciences & Peking Union Medical College · CNNew York University · USNational Institute of Dental and Craniofacial Research · US

Funding

TGF-beta Regulation of Mucosal and Systemic T Cell Immunity and ToleranceZIADE000101 · NIDCR · NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH · PI CHEN, WANJUN · 2009 to 2025
$36.9M
Validation of the Rev-dependent vector for targeting SIV macrophage reservoirsR01MH102144 · NIMH · GEORGE MASON UNIVERSITY · PI WU, YUNTAO · 2014 to 2018
$3.3M
Establishing HIV-1 chromatin in resting T cells: Vpr, latency, and H2A.ZR01AI145753 · NIAID · NEW YORK UNIVERSITY · PI LEVY, DAVID N · 2019 to 2023
$2.0M
Viruis Dynamics and Multiple Infection of Cells: Computational and Experimental AR01AI093998 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI LEVY, DAVID N, WODARZ, DOMINIK F · 2011 to 2014
$1.5M
The contribution of unintegrated HIV-1 to latency and to models of latencyR56AI118453 · NIAID · NEW YORK UNIVERSITY · PI LEVY, DAVID N · 2015 to 2015
$396k
Development of a novel HIV-1 nuclear localization assayR03AI110174 · NIAID · GEORGE MASON UNIVERSITY · PI WU, YUNTAO · 2014 to 2015
$142k
NIAID NIH HHS R01 AI093998NIAID NIH HHS R01 AI145753NIAID NIH HHS R03 AI110174NIAID NIH HHS R56 AI118453NIMH NIH HHS R01 MH102144
6 · The paper itself

Abstract

A functional HIV cure requires immune reconstitution for lasting viremia control. A major immune dysfunction persisting in HIV infection is the impairment of T helper cell migration and homing to lymphoid tissues such as GALTs (gut-associated lymphoid tissues). ART (antiretroviral therapy) does not fully restore T cell motility for tissue repopulation. The molecular mechanism dictating this persistent T cell dysfunction is not understood. Cofilin is an actin-depolymerizing factor that regulates actin dynamics for T cell migration. Here, we demonstrate that blood CD4 T cells from HIV-infected patients (

Indexed as

Actin Depolymerizing FactorsAntibodiesAntirheumatic AgentsCD4-Positive T-LymphocytesCell MovementCell PolarityCohort StudiesHEK293 CellsHIV-1HIV InfectionsHumansIntegrinsLim KinasesOkadaic AcidPhosphorylationReceptors, CCR5Actin Depolymerizing FactorsAntibodiesAntirheumatic AgentsCCR5 protein, humanintegrin alpha4beta7IntegrinsLIMK1 protein, humanLim KinasesOkadaic AcidReceptors, CCR5

Identifiers

PMID30662943
PMCPMC6326757
OpenAlexW2908522009

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.